Endometrial Cancer Therapy Combo Fails 1L Treatment Trial Endometrial Cancer Therapy Combo Fails 1L Treatment Trial
Merck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line treatment for a type of cancer in the uterus lining.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Merck's Lung Cancer Drug Combo Fails Trial Merck's Lung Cancer Drug Combo Fails Trial
Merck said on Thursday a combination treatment testing a new type of immunotherapy failed to significantly slow disease progression in lung cancer patients who did not respond to previous treatments.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Court Rules Merck, Not Bayer Responsible in Talc Lawsuits
Bayer AG was absolved of liability in certain cancer-related lawsuits. The cases concern talc-based foot powders that the company acquired from Merck & Co. in a more than $14 billion cash deal nearly a decade ago. Delaware’s highest court clarified that Merck is responsible for claims that predate Bayer’s acquisition. Lawsuits claim talc used in products like Dr. Scholl’s caused cancer.  Talc-based products have been linked in recent years to asbestos-related illnesses such as ovarian cancer, mesothelioma and asbestosis. Merck, Bayer and Johnson & Johnson have faced lawsuits claiming talc-based pro...
Source: Asbestos and Mesothelioma News - December 5, 2023 Category: Environmental Health Authors: Amy Edel Tags: Asbestos (general) Legal Source Type: news

European Pharmas With New Drugs Hold Most Promise in 2024
European pharmaceutical and biotech companies with new drugs and higher growth prospects look the best investment bets in the sector in 2024, JPMorgan says. JPM is avoiding companies like Bayer and Roche, which might struggle to match 2024…#jpmorgan #jpm #bayer #roche #gsk #novonordisk #astrazeneca #merck #argenx #morphosys (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2023 Category: Consumer Health News Source Type: news

Let's Talk Drug Prices; Restoring the Sense of Touch; Learning From Tumors in a Dish
(MedPage Today) -- Sen. Bernie Sanders (I-Vt.) has invited CEOs of Johnson & Johnson, Merck, and Bristol Myers Squibb to testify next month at a hearing on drug pricing, specifically to discuss why the U.S. pays so much more than other countries... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 2, 2023 Category: Hematology Source Type: news

Meet Johanna Herrmann, a 2023 40 Under 40 honoree
Johanna Herrmann is the vice president, global communications, and chief of staff to the executive vice president and chief communications and public affairs officer at Merck a 2023 40 Under 40 honoree. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 1, 2023 Category: Pharmaceuticals Authors: Devonta Davis Source Type: news

Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times
Go for more of a sure thing At first blush, focusing on low-volatility stocks may appear an overly pessimistic strategy. After all, the benchmark S&P 500 gained almost 8% in the trailing month. On a year-to-date basis, the venerable index is up nearly 19%, very close to its record high.…#proctergamble #ttm #merck #verizon #dukeenergy #duk #duke #gurufocus #dukesaltmanzscore #kellanova (Source: Reuters: Health)
Source: Reuters: Health - November 23, 2023 Category: Consumer Health News Source Type: news

FDA Panel Flags Insufficient Data for Chronic Cough Drug FDA Panel Flags Insufficient Data for Chronic Cough Drug
Advisers to the FDA said that data on Merck ' s chronic cough drug do not provide sufficient evidence to prove its clinical benefit for patients.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2023 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

FDA AdComm votes against Merck's cough med
An FDA advisory committee has voted against approving Merck & Co.’s gefapixant, a P2X3 receptor antagonist medicine designed to treat adults with chronic cough. The 12-1 vote is meant to help guide the FDA in its approval decision, which is set to be made by Dec. 27. There currently aren’t any…#fda #merckcos #merck #newjersey #markcourey #mountsinai #leonardbacharier #p030 #p027 #paulacarvalho (Source: Reuters: Health)
Source: Reuters: Health - November 19, 2023 Category: Consumer Health News Source Type: news

How R.F.K. Jr. Turned Public Crusades Into a Private Windfall
Robert F. Kennedy Jr. has said he is driven by his family’s legacy of public service and good works.Credit...Sophie Park for The New York Times The causes Robert F. Kennedy Jr. has championed have brought him admiration, criticism — and tens of millions of dollars. Robert F. Kennedy Jr. has said…#robertfkennedyjr #johnfkennedy #tedkennedy #robertfkennedy #merck #alansalzman #times #vantagepoint #sienacollege #donaldjtrump (Source: Reuters: Health)
Source: Reuters: Health - November 18, 2023 Category: Consumer Health News Source Type: news

CDC Claims On Vaccination And Natural Immunity Made Without Seeing Underlying Data: FOIA Document
Authored by Hans Mahncke via The Epoch Times (emphasis ours), In a new Freedom of Information Act (FOIA) response, the Centers for Disease Control and Prevention (CDC) now admits that it recommended…#cdc #foiadocumentauthored #hansmahncke #epochtimes #foia #atlanta #ericbaradatafp #pfizer #astrazeneca #merck (Source: Reuters: Health)
Source: Reuters: Health - November 18, 2023 Category: Consumer Health News Source Type: news

Merck Provides Update on FDA Advisory Committee Meeting Evaluating Gefapixant
RAHWAY, N.J., Nov. 17, 2023– Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the outcome of the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) meeting, which... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 17, 2023 Category: Drugs & Pharmacology Source Type: news

FDA Approves Merck ’s Keytruda (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone Approval marks seventh gastrointestinal cancer indication for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 16, 2023 Category: Drugs & Pharmacology Source Type: news

FDA approves pembrolizumab with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma  
On November 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 16, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Staff Flags Concerns on Merck's Chronic Cough Drug FDA Staff Flags Concerns on Merck's Chronic Cough Drug
The U.S. health regulator ' s staff on Wednesday flagged concerns that data on Merck ' s chronic cough drug might not be enough to prove the treatment ' s meaningful benefit.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news